Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Chembio's Dual Path Platform (DPP) patent application allowed
February 14th, 2007
Chembio Diagnostics, Inc. (CEMI) has received a Notice of Allowance from the United States Patent and Trademark Office for its Dual Path Immunoassay patent application publication #2006-0205059. The patent application describes Chembio's innovative Dual Path Platform (DPP) lateral flow rapid diagnostic test system. Chembio is developing its next generation infectious disease rapid tests using DPP. Chembio also believes that its DPP diagnostic test system can be licensed to other manufacturers that seek enhanced rapid test performance or where licenses to other lateral flow technologies are not as cost-effective or even available. By employing a...
Source: Medical Patent Law Weekly (2007-02-14)
|
